Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

References

• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–70. doi:10.1038/nbt.2287.
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–67. doi:10.1038/nrc3770.
   PubMed Web of Science ®Google Scholar
• Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12(1):103. doi:10.1186/1476-4598-12-103.
   PubMed Web of Science ®Google Scholar
• Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014; 22(2):251–6. doi:10.1038/mt.2013.220.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell research. 2017;27(1):11–37. doi:10.1038/cr.2016.155.
   PubMed Web of Science ®Google Scholar
• Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187(2):265–70. doi:10.1084/jem.187.2.265.
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698–703. doi:10.1056/NEJMoa0800251.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21. doi:10.1038/nm.3910.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–27. doi:10.1158/1078-0432.CCR-14-2708.
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Brilot F, Munz C, Gannage M. The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer. J Immunol. 2016;196(1):64–71. doi:10.4049/jimmunol.1402664.
   PubMed Web of Science ®Google Scholar
• Munz C. Autophagy proteins in antigen processing for presentation on MHC molecules. Immunological reviews. 2016;272(1):17–27. doi:10.1111/imr.12422.
   PubMed Web of Science ®Google Scholar
• Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM, Erbs P. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 2008;15(20):1361–71. doi:10.1038/gt.2008.82.
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer cell. 2003;4(4):263–75. doi:10.1016/S1535-6108(03)00241-1.
   PubMed Web of Science ®Google Scholar
• Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther. 2010;18(5):888–95. doi:10.1038/mt.2010.44.
   PubMed Web of Science ®Google Scholar
• Kambara H, Okano H, Chiocca EA, Saeki Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005;65(7):2832–9. doi:10.1158/0008-5472.CAN-04-3227.
   PubMed Web of Science ®Google Scholar
• Venskus D, Kalvins I, Pjanova D, Petrovska R, Auzins J. Genetically stable oncolytic RNA virus, method of manufacturing and use thereof. European patent EP2826856. 2013 July 16.
   Google Scholar
• Coffin RS. From virotherapy to oncolytic immunotherapy: Where are we now? Curr Opin Virol. 2015;13:93–100. doi:10.1016/j.coviro.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Achard C, Zaupa C, Foloppe J, Erbs P. Oncolytic immunotherapy: The new clinical outbreak. Oncoimmunology. 2015;5(1). e1066961. doi:10.1080/2162402X.2015.1066961.
   PubMed Web of Science ®Google Scholar
• Achard C, Boisgerault N, Delaunay T, Tangy F, Grégoire M, Fonteneau JF. Induction of immunogenic tumor cell death by attenuated oncolytic measles virus. J Clin Cell Immunol. 2015;6:291.
   Google Scholar
• Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013 Jan;20(1):7–15. doi:10.1038/gt.2011.205.
   PubMed Web of Science ®Google Scholar
• Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res. 2008;68(12):4882–92. doi:10.1158/0008-5472.CAN-07-6265.
   PubMed Web of Science ®Google Scholar
• Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F, Fonteneau JF, Gregoire M. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res. 2013;19(5):1147–58. doi:10.1158/1078-0432.CCR-12-2733.
   PubMed Web of Science ®Google Scholar
• Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75(1):22–30.. doi:10.1158/0008-5472.CAN-14-2533.
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19(3):329–36. doi:10.1038/nm.3089.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, et al. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Annals of surgical oncology. 2016;23(13):4169–77. doi:10.1245/s10434-016-5286-0.
   PubMed Web of Science ®Google Scholar
• Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert E, et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 2004;10(24):8396–404. doi:10.1158/1078-0432.CCR-04-0809.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34(22):2619–26. doi:10.1200/JCO.2016.67.1529.
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Larsson M, Somersan S, Sanders C, Munz C, Kwok WW, Bhardwaj N, Jotereau F. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. Journal of immunological methods. 2001;258(1-2):111–26. doi:10.1016/S0022-1759(01)00477-X.
   PubMed Web of Science ®Google Scholar
• Davodeau F, Difilippantonio M, Roldan E, Malissen M, Casanova JL, Couedel C, Morcet JF, Merkenschlager M, Nussenzweig A, Bonneville M, et al. The tight interallelic positional coincidence that distinguishes T-cell receptor Jalpha usage does not result from homologous chromosomal pairing during ValphaJalpha rearrangement. EMBO J. 2001;20(17):4717–29. doi:10.1093/emboj/20.17.4717.
   PubMed Web of Science ®Google Scholar
• Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42(6):455–500.
   PubMedGoogle Scholar
• Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M, Tangy F. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol. 2003;77(21):11546–54. doi:10.1128/JVI.77.21.11546-11554.2003.
   PubMed Web of Science ®Google Scholar
• Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther. 2010;18(6):1123–9. doi:10.1038/mt.2010.67.
   PubMed Web of Science ®Google Scholar
• Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: An open-source platform for biological-image analysis. Nature methods. 2012;9(7):676–82. doi:10.1038/nmeth.2019.
   PubMed Web of Science ®Google Scholar